Last reviewed · How we verify
Tigecycline antimicrobial-lock solution
Tigecycline antimicrobial-lock solution is a Tetracycline antibiotic Small molecule drug developed by Clinica Universidad de Navarra, Universidad de Navarra. It is currently FDA-approved for Prevention and treatment of catheter-related bloodstream infections (CRBSI) in central venous catheters. Also known as: tigecycline: tygacil 50 mg vial., sodium chloride 0,9% 10 ml vial., sodium heparin 1%, 5000 IU/5ml..
Tigecycline is a broad-spectrum antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing peptide bond formation.
Tigecycline is a small molecule inhibitor that works by targeting the bacterial 70S ribosome. It has been studied as an antimicrobial-lock solution for conditions such as catheter-related infections, bacteremia, and hemodialysis catheter-related bacteremia.
At a glance
| Generic name | Tigecycline antimicrobial-lock solution |
|---|---|
| Also known as | tigecycline: tygacil 50 mg vial., sodium chloride 0,9% 10 ml vial., sodium heparin 1%, 5000 IU/5ml. |
| Sponsor | Clinica Universidad de Navarra, Universidad de Navarra |
| Drug class | Tetracycline antibiotic |
| Target | Bacterial 30S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
As a tetracycline-class antimicrobial, tigecycline binds to bacterial ribosomes and blocks translation of mRNA into proteins, effectively halting bacterial growth. When formulated as an antimicrobial-lock solution, it is instilled into central venous catheters to prevent and treat catheter-related bloodstream infections by maintaining high local antibiotic concentrations at the catheter tip.
Approved indications
- Prevention and treatment of catheter-related bloodstream infections (CRBSI) in central venous catheters
Common side effects
- Photosensitivity
- Nausea
- Vomiting
- Diarrhea
- Tooth discoloration (with systemic use)
Key clinical trials
- Treatment of Hemodialysis Catheter-Related Bacteremia (PHASE2, PHASE3)
- Concentration of Antimicrobials in Catheter-lock Solutions (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tigecycline antimicrobial-lock solution CI brief — competitive landscape report
- Tigecycline antimicrobial-lock solution updates RSS · CI watch RSS
- Clinica Universidad de Navarra, Universidad de Navarra portfolio CI
Frequently asked questions about Tigecycline antimicrobial-lock solution
What is Tigecycline antimicrobial-lock solution?
How does Tigecycline antimicrobial-lock solution work?
What is Tigecycline antimicrobial-lock solution used for?
Who makes Tigecycline antimicrobial-lock solution?
Is Tigecycline antimicrobial-lock solution also known as anything else?
What drug class is Tigecycline antimicrobial-lock solution in?
What development phase is Tigecycline antimicrobial-lock solution in?
What are the side effects of Tigecycline antimicrobial-lock solution?
What does Tigecycline antimicrobial-lock solution target?
Related
- Drug class: All Tetracycline antibiotic drugs
- Target: All drugs targeting Bacterial 30S ribosomal subunit
- Manufacturer: Clinica Universidad de Navarra, Universidad de Navarra — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Prevention and treatment of catheter-related bloodstream infections (CRBSI) in central venous catheters
- Also known as: tigecycline: tygacil 50 mg vial., sodium chloride 0,9% 10 ml vial., sodium heparin 1%, 5000 IU/5ml.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing